Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed SBRT

It is unknown how changes in the Tumor-Reactive T-cell subpopulation (CD8+PD-1+CD11ahigh) correlate with clinical outcomes after metastasis-directed stereotactic body radiation therapy (mdSBRT) for patients with recurrent oligometastatic prostate cancer (OPCa). In this prospective trial of 37 patients with OPCa treated with mdSBRT, an increase in the Tumor-Reactive T-cell subpopulation after mdSBRT was protective against the risk of disease progression. These data have clinical implications for combining mdSBRT with anti-PD-1 therapy and/or adoptive cell transfer procedures.

https://ift.tt/2MayTP1